Related Experiment Video

Updated: May 28, 2026

Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles
05:55

Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Stable and orally bio-available pro-drugs of CPS11

Aihong Huo1, Hesheng Zhang, Yongbiao Guan

  • 1Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.

Bioorganic & Medicinal Chemistry Letters
|October 4, 2011
PubMed

Insights

New pro-drugs of CPS11 show promise for cancer therapy. Compound 4, when combined with Taxol, significantly enhanced anti-tumor activity in breast cancer models, suggesting a potential synergistic treatment approach.

Area of Science:

  • Pharmacology and Medicinal Chemistry
  • Oncology
  • Biotechnology

Background:

  • CPS11 is a target for cancer therapy.
  • Developing orally bio-available pro-drugs can improve drug delivery and efficacy.
  • Combination therapies often yield better outcomes than single agents.

Purpose of the Study:

  • To synthesize stable and orally bio-available pro-drugs of CPS11.
  • To evaluate the in vitro activity of these pro-drugs.
  • To assess the therapeutic efficacy and safety of a lead compound (Compound 4) in combination with Taxol for breast cancer treatment.

Main Methods:

  • Synthesis of CPS11 pro-drugs.
  • In vitro assays: human umbilical vein endothelial cell proliferation and tube formation.
  • In vivo study using MX-1 human breast cancer xenograft model in mice.
  • Evaluation of Compound 4 as a single agent and in combination with Taxol.

Main Results:

  • Synthesized pro-drugs of CPS11 were stable and orally bio-available.
  • The pro-drugs demonstrated activity in endothelial cell proliferation and tube formation assays.
  • Compound 4 alone did not show significant anti-tumor activity against the breast cancer xenograft.
  • Combination of Compound 4 with Taxol significantly enhanced the anti-tumor potency compared to Taxol alone.

Conclusions:

  • Orally bio-available CPS11 pro-drugs can be successfully synthesized.
  • Compound 4 exhibits synergistic effects when combined with Taxol in a preclinical breast cancer model.
  • This combination therapy warrants further investigation for breast cancer treatment.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).